Compare OVLY & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OVLY | OBIO |
|---|---|---|
| Founded | 1990 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.7M | 246.2M |
| IPO Year | 2008 | 2020 |
| Metric | OVLY | OBIO |
|---|---|---|
| Price | $34.32 | $4.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.25 |
| AVG Volume (30 Days) | 24.2K | ★ 153.6K |
| Earning Date | 04-23-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.16% | N/A |
| EPS Growth | N/A | ★ 33.13 |
| EPS | ★ 2.88 | N/A |
| Revenue | N/A | ★ $33,482,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.43 |
| P/E Ratio | $12.03 | ★ N/A |
| Revenue Growth | N/A | ★ 1169.22 |
| 52 Week Low | $23.65 | $2.20 |
| 52 Week High | $34.96 | $5.42 |
| Indicator | OVLY | OBIO |
|---|---|---|
| Relative Strength Index (RSI) | 65.86 | 53.38 |
| Support Level | $32.81 | $4.02 |
| Resistance Level | N/A | $4.76 |
| Average True Range (ATR) | 0.59 | 0.23 |
| MACD | 0.20 | 0.02 |
| Stochastic Oscillator | 83.24 | 72.41 |
Oak Valley Bancorp is a bank holding company that operates through Oak Valley Community Bank (the Bank). The Bank offers a complement of business checking and savings accounts for its business customers. The Bank also offers commercial and real estate loans, as well as lines of credit. In addition, the bank provides other services for both individuals and businesses including online banking, remote deposit capture, mobile banking, merchant services, night depository, extended hours, wire transfer of funds, note collection, and automated teller machines in a national network. Its primary source of revenue is net interest income.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.